Trial Profile
A Phase II Clinical Study to Assess the Safety, Immunogenicity, and Efficacy of Blood-stage Plasmodium Vivax Malaria Vaccine Candidate PvRII/Matrix-M in Healthy Thai Adults Living in Thailand
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Dec 2023
Price :
$35
*
At a glance
- Drugs PvRII (Primary) ; Matrix M
- Indications Vivax malaria
- Focus Adverse reactions; Therapeutic Use
- Acronyms MIST3
- 04 Dec 2023 Planned initiation date changed from 1 Sep 2023 to 1 Feb 2024.
- 19 Apr 2023 Planned primary completion date changed from 30 May 2024 to 1 May 2024.
- 19 Apr 2023 Planned initiation date changed from 1 Mar 2023 to 1 Sep 2023.